Promoted Companies
SORT BY:
Ventrus Biosciences Inc. (VTUS)
| Total paid for Promotions this month: | $0 | ||
| E-mails this Month: | 1 | ||
| Estimated Volume Generated: | $0 | ||
| Research Report on VTUS: | Click to see | ||
| * The information presented is based on information for May , 2014 | |||
Merger to Create a Robust Biopharmaceutical Company May 19, 2014 08:17
Merger to Create a Robust Biopharmaceutical Company
(Mailing list information, including unsubscription instructions, is located at the end of this message.)
Ventrus Biosciences Inc. (VTUS)
VTUS reported that it has entered into a merger agreement with Assembly Pharmaceuticals in an all-stock transaction.
Once the merger is complete, the company will focus on the development of Assembly's novel, first-in-class small molecules
...read more
| Promoter: | pennyomega.com | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| VTUS | Unknown compensation | UNKNOWN |
| Max Profit: 1.82 % | Gain at close: -19.85 % |
StockStars.net Thursday Night Watch List Feb 13, 2014 22:40
Monday night's alert IO reported strong 4th quarter results and the stock is up 29% on record volume. How's that for a start to my alerts?
I also want to take a moment to clarify the frequency of my emails going forward. It's tough to find good opportunities on a daily basis, so from now on, I will just issue alerts when I find something worth while.
That said, I may have found a company with explosive
...read more
| Promoter: | Stock Stars | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| VTUS | Unknown compensation | UNKNOWN |
| Max Profit: 0.62 % | Gain at close: -2.47 % |
VTUS - Ventrus Biosciences, Inc. Phase III Results are Expected for... Feb 03, 2014 09:36
VTUS - Ventrus Biosciences, Inc. Phase III Results are Expected for 2nd Study
www.GreatStockAlerts.com
Recent Winners: $CYTR 2.20-6.79 an 208% increase in pps from our alert. ATHX 48% and DRRX Over 15%..
VTUS closed at $4.24 on Friday afternoon. Phase III results are due soon for their second study. First one was very successful. I think a high probability of success.
VTUS - Ventrus Biosciences,
...read more
| Promoter: | @PennyStockAlerts | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| VTUS | Unknown compensation | UNKNOWN |
| Max Profit: 2.09 % | Gain at close: -4.88 % |
VTUS - PennyToBuck.com Watch List For Monday Nov. 21, 2011 Nov 20, 2011 18:18
VTUS, Ventrus BioSciences, Inc.
** VTUS reported that it has completed its acquisition of all rights and title to VEN 309 (iferanserin ointment for the topical treatment of symptomatic hemorrhoids) from the licensor, Sam Amer & Co.
The acquisition enables VTUS to reduce royalties by approximately 66% and aggregate milestone payments by approximately 50% (from $20 million to $10.5 million) compared
...read more
| Promoter: | penny to buck | Paying Party: | No Third Party |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| VTUS | No compensation | UNKNOWN |
| Max Profit: 3.00 % | Gain at close: Pending |
Ventrus BioSciences (VTUS) - CRWESelect.com Stock To Watch For... Nov 20, 2011 18:16
VTUS, Ventrus BioSciences, Inc.
** VTUS reported that it has completed its acquisition of all rights and title to VEN 309 (iferanserin ointment for the topical treatment of symptomatic hemorrhoids) from the licensor, Sam Amer & Co.
The acquisition enables VTUS to reduce royalties by approximately 66% and aggregate milestone payments by approximately 50% (from $20 million to $10.5 million) compared
...read more
| Promoter: | Crweselect.com | Paying Party: | No Third Party |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| VTUS | No compensation | UNKNOWN |
| Max Profit: 3.00 % | Gain at close: Pending |